Intravenous Thrombolysis for Acute Stroke: Current Standards and Future Directions
详细信息 查看全文
- 作者：Lucille Ramani MBChB ; BSc (1)
Xuya Huang MBBS ; MRCP (1)
Bharathkumar Cheripelli MBBS ; MRCP (1)
Keith W. Muir MD ; FRCP (1)
1. Institute of Neuroscience and Psychology ; University of Glasgow ; Southern General Hospital ; 1345 Govan Road ; Glasgow ; G51 3TF ; Scotland ; UK - 关键词：Intravenous thrombolysis ; Acute ischaemic stroke ; Treatment ; Recombinant tissue plasminogen activator alteplase
- 刊名：Current Treatment Options in Cardiovascular Medicine
- 出版年：2015
- 出版时间：April 2015
- 年：2015
- 卷：17
- 期：4
- 全文大小：454 KB
- 参考文献：1. Murray, CJ, Lopez, AD (1997) Alternative projections of mortality and disability by cause 1990鈥?020: Global Burden of Disease Study. Lancet 349: pp. 1498-1504 CrossRef
2. Wechsler, LR (2011) Intravenous thrombolytic therapy for acute ischemic stroke. N Engl J Med 364: pp. 2138-2146 CrossRef
3. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med, 1995. 333(24): p. 1581鈥?.
4. Hacke, W (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363: pp. 768-74 CrossRef
5. Hacke, W (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359: pp. 1317-1329 CrossRef
6. Sandercock, P (2012) The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 379: pp. 2352-63 CrossRef
7. Emberson J, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014. A recent post-IST3 meta analysis, which showed the consistent finding of improved outcomes with earlier treatment, in age >80 years population, and across all stroke severities.
8. US Food and Drug Administration (FDA). Alteplase product approval information-licensing action 6/18/96. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080430.htm. Accessed 13 July.
9. Swieten, JC (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19: pp. 604-607 CrossRef
10. Wahlgren, N (2007) Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369: pp. 275-282 CrossRef
11. Jauch, EC (2013) Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44: pp. 870-947 CrossRef
12. National Institute for Health and Care Excellence. Alteplase for treating acute ischaemic stroke (review of technology appraisal guidance 122 TA264). London: National Institute for Health and Care Excellence 2012.
13. Scottish Intercollegiate Guidelines Network (SIGN). Antithrombotics: indications and management. Edinburgh: SIGN; 2012. (SIGN publication no. 129).
14. Intercollegiate Stroke Working Party. National clinical guideline for stroke, 4th edition. London: Royal College of Physicians, 2012.
15. European Stroke Organisation. ESO Guidelines for the Management of Ischaemic Stroke. Basel: European Stroke Organisation 2008, updated in 2009.
16. Frank, B (2013) Thrombolysis in stroke despite contraindications or warnings?. Stroke 44: pp. 727-33 CrossRef
17. Brott, T (1997) Generalized efficacy of t-PA for acute stroke鈥攕ubgroup analysis of the NINDS t-PA stroke trial. Stroke 28: pp. 2119-2125 CrossRef
18. Smith, EE (2005) Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 36: pp. 2497-9 CrossRef
19. Mishra, NK (2010) Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke 41: pp. 2840-2848 CrossRef
20. Mishra NK et al. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ 2010. 341: p. c6046.
21. Wardlaw, JM (2012) Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 379: pp. 2364-72 CrossRef
22. Mishra, NK (2010) Comparison of outcomes following thrombolytic therapy among patients with prior stroke and diabetes in the Virtual International Stroke Trials Archive (VISTA). Diabetes Care 33: pp. 2531-7 CrossRef
23. Cronin, CA (2012) No increased risk of symptomatic intracerebral hemorrhage after thrombolysis in patients with European Cooperative Acute Stroke Study (ECASS) exclusion criteria. Stroke 43: pp. 1684-6 CrossRef
Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 346: pp. 1509-1514 CrossRef
24. Zinkstok, SM, Roos, YB (2012) Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet 380: pp. 731-7 CrossRef
25. Larrue, V (2001) Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator鈥攁 secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 32: pp. 438-441 CrossRef
26. Cucchiara, B (2009) Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials. Stroke 40: pp. 3067-72 CrossRef
27. Diedler, J (2010) Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke 41: pp. 288-94 CrossRef
28. Miedema, I (2012) Thrombolytic therapy for ischaemic stroke in patients using warfarin: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 83: pp. 537-40 CrossRef
29. Xian, Y (2012) Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 307: pp. 2600-8 CrossRef
30. Ahmed, N (2010) Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR). Arch Neurol 67: pp. 1123-30 CrossRef
31. Ahmed, N (2009) Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke 40: pp. 2442-9 CrossRef
32. Kent, DM (2006) The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke 37: pp. 2957-2962 CrossRef
33. Castillo, J (2004) Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke 35: pp. 520-6 CrossRef
34. Stroke Unit Trialists, C., Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2013. 9: p. CD000197.
35. Astrup, J, Siesjo, BK, Symon, L (1981) Thresholds in cerebral ischemia鈥攖he ischemic penumbra. Stroke 12: pp. 723-725 CrossRef
36. Jones, TH (1981) Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 54: pp. 773-782 CrossRef
37. Saver, JL (2010) The "golden hour" and acute brain ischemia: presenting features and lytic therapy in >30,000 patients arriving within 60 minutes of stroke onset. Stroke 41: pp. 1431-1439 CrossRef
38. Lees, KR (2010) Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375: pp. 1695-703 CrossRef
39. Ebinger, M (2012) PHANTOM-S: the prehospital acute neurological therapy and optimization of medical care in stroke patients - study. Int J Stroke 7: pp. 348-53
40. Walter, S (2012) Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol 11: pp. 397-404 CrossRef
41. Stroke Care Audit. Scottish Stroke Care Standards 2013. http://www.strokeaudit.scot.nhs.uk/Quality/130311_ScottishStrokeCareStandards_2013_FinalVersion.pdf. Accessed 02 Aug 2014.
42. Roffe C, Bhalla A, Barrick H, Gompertz P, Coull A, Hasan M, et al. British Association of Stroke Physicians (BASP): Clinical Standards Committee 2013. http://www.basp.ac.uk/LinkClick.aspx?fileticket=I3ONhEDRGi8%3D&tabid=102&mid=521. Accessed 02 Aug 2014.
43. Ahmed, N (2010) Implementation and outcome of thrombolysis with alteplase 3鈥?.5聽h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 9: pp. 866-874 CrossRef
44. Fonarow, GC (2011) Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation 123: pp. 750-758 CrossRef
45. Fonarow, GC (2011) Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: Stroke Initiative. Stroke 42: pp. 2983-U493 CrossRef
46. Monks T, et al. Maximizing the population benefit from thrombolysis in acute ischemic stroke: a modeling study of in-hospital delays. Stroke 2012.
47. Meretoja, A (2012) Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology 79: pp. 306-313 CrossRef
48. Price, CI (2009) Systematic review of stroke thrombolysis service configuration. Expert Rev Neurother 9: pp. 211-33 CrossRef
49. Meretoja, A (2014) Stroke thrombolysis: save a minute. Save a Day Stroke 45: pp. 1053-1058 CrossRef
50. Mazya M. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: Safe Implementation of Treatments in Stroke (SITS) Symptomatic Intracerebral Hemorrhage Risk Score (vol 43, pg 1524, 2012). Stroke, 2012. 43(9): p. E102-E102.
51. Whiteley, WN (2014) Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial. Stroke 45: pp. 1000-6 CrossRef
52. Donnan, GA (2009) Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol 8: pp. 261-269 CrossRef
53. Parsons, MW (2012) A randomised trial of tenecteplase versus alteplase for acute ischaemic stroke. NEngl J Med 366: pp. 1099-1107 CrossRef
54. Lansberg, MG (2012) MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol 11: pp. 860-867 CrossRef
55. Kidwell, C (2013) A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 368: pp. 914-923 CrossRef
56. Hacke, W (2009) Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 8: pp. 141-150 CrossRef
57. Albers, GW (2006) Magnetic resonance imaging profiles predict clinical response to early reperfusion: the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. Ann Neurol 60: pp. 508-517 CrossRef
58. Davis, SM (2008) Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 7: pp. 299-309 CrossRef
59. Ogata, T (2013) The effects of alteplase 3 to 6 hours after stroke in the EPITHET-DEFUSE combined dataset post hoc case-control study. Stroke 44: pp. 87-93 CrossRef
60. Mishra, NK (2010) Mismatch-based delayed thrombolysis: a meta-analysis. Stroke 41: pp. e25-33 CrossRef
61. Dani, AK (2011) Computed tomography and magnetic resonance perfusion imaging in ischemic stroke: definitions and thresholds. Ann Neurol 70: pp. 384-401 CrossRef
62. Lansberg, MG (2011) RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. Stroke 42: pp. 1608-14 CrossRef
63. Ma, H (2012) A multicentre, randomized, double-blinded, placebo-controlled phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke 7: pp. 74-80 CrossRef
64. Hopyan, J (2010) Certainty of stroke diagnosis: incremental benefit with CT perfusion over noncontrast CT and CT angiography. Radiology 255: pp. 142-153 CrossRef
65. Coutts, SB (2009) Computed tomography and computed tomography angiography findings predict functional impairment in patients with minor stroke and transient ischaemic attack. Int J Stroke 4: pp. 448-453 CrossRef
66. Silva, GS (2010) Wake-up stroke: clinical and neuroimaging characteristics. Cerebrovasc Dis 29: pp. 336-342 CrossRef
67. Ebinger, M (2012) MRI-based intravenous thrombolysis in stroke patients with unknown time of symptom onset. Eur J Neurol 19: pp. 348-350 CrossRef
68. Aoki, J (2011) Intravenous thrombolysis based on diffusion-weighted imaging and fluid-attenuated inversion recovery mismatch in acute stroke patients with unknown onset time. Cerebrovasc Dis 31: pp. 435-41 CrossRef
69. Thomalla, G (2011) DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4.5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurol 10: pp. 978-86 CrossRef
70. Haley, EC (2005) A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 36: pp. 607-612 CrossRef
71. Parsons, MW (2009) Acute ischemic stroke: imaging guided tenecteplase treatment in an extended time window. Neurology 72: pp. 915-21 CrossRef
72. Haley, EC (2010) Phase IIB/III trial of tenecteplase in acute ischemic stroke results of a prematurely terminated randomized clinical trial. Stroke 41: pp. 707-711 CrossRef
73. Huang, X (2014) Alteplase-tenecteplase trial evaluation for stroke thrombolysis (ATTEST)鈥攑ilot phase. Cerebrovasc Dis 37: pp. 179
74. Hacke, W (2005) The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36: pp. 66-73 CrossRef
75. Furlan, AJ (2006) Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 37: pp. 1227-1231 CrossRef
76. Mori, E (2012) Safety and efficacy of 0.6 mg/kg rt-PA: optimum rt-PA dose revisited. Ann N Y Acad Sci 1268: pp. 108-12 CrossRef
77. Yamaguchi, T (2006) Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 37: pp. 1810-5 CrossRef
78. Mori, E (2010) Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke 41: pp. 461-5 CrossRef
79. Nakagawara, J (2010) Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 41: pp. 1984-9 CrossRef
80. Chao, AC (2010) Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study. Stroke 41: pp. 885-90 CrossRef
81. Sharma, VK (2010) Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore. J Stroke Cerebrovasc Dis 19: pp. 424-30 CrossRef
82. Liao X, et al. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses. Stroke 2014.
83. Absar, S (2013) Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy. Pharm Res 30: pp. 1663-76 CrossRef
84. Lian, T, Ho, RJ (2001) Trends and developments in liposome drug delivery systems. J Pharm Sci 90: pp. 667-80 CrossRef
85. Goyal M, Demchuk AM, Menon BK, et al. Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke. N Engl J Med. 2015. doi: 10.1056/NEJMoa1414905 .
86. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection. N Engl J Med. 2015. doi: 10.1056/NEJMoa1414792 .
87. Berkhemer OA, Fransen PS, Beumer D, et al. A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke. N Engl J Med. 2015; 372(1): 11鈥?0.
88. Ciccone, A (2010) Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. J Neurointerv Surg 2: pp. 74-9 CrossRef
89. Broderick, JP (2013) Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 368: pp. 893-903 CrossRef
90. Alexandrov, AV, Wojner, AW, Grotta, JC (2004) CLOTBUST: design of a randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke. J Neuroimaging 14: pp. 108-12 CrossRef
91. Tsivgoulis, G (2010) Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke 41: pp. 280-7 CrossRef
92. Molina, CA (2009) Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. Ann Neurol 66: pp. 28-38 CrossRef
93. Pancioli, AM (2008) The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke 39: pp. 3268-3276 CrossRef
94. Sugg, RM (2006) Argatroban tPA stroke study鈥攕tudy design and results in the first treated cohort. Arch Neurol 63: pp. 1057-1062 CrossRef - 刊物主题：Cardiology;
- 出版者：Springer US
- ISSN：1534-3189
文摘